Dabur Pharma Ltd on March 11, 2008 has announced that it has received approvals for Irinotecan Hydrochloride Injection in Italy and Denmark.

The Company had successfully launched the generic version of the drug in the US recently, being amongst the first of a handful of companies to do so. It also has approval for the drug in the UK.

Speaking on the occasion, Chief Executive Officer, Dabur Pharma Ltd., Mr. Ajay Kumar Vij said “We are extremely pleased to receive these approvals for Irinotecan across Europe. This bear testimony to the strong foundation we are laying towards becoming one of the leading oncology players across the globe.

Irinotecan Hydrochloride Injection is the generic version of Pfizer’s Camptosar?. It is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum. It is also indicated for patients with metastatic carcinoma of the colon or rectum where disease has recurred or progressed following initial fluorouracil based therapy.